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Abstract
Progestin resistance is a major obstacle to treating early stage, well-differentiated endometrial cancer as well as recurrent
endometrial cancer. The mechanism behind the suboptimal response to progestin is not well understood. The PTEN tumor
suppressor gene is frequently mutated in type I endometrial cancers and this mutation results in hyperactivation of the
PI3K/AKT pathway. We hypothesized that increased activation of AKT promotes an inadequate response to progestins in
endometrial cancer cells. Ishikawa cells stably transfected with progesterone receptor B (PRB23 cells) were treated with the
AKT inhibitor, MK-2206, which effectively decreased levels of p(Ser473)-AKT in a dose-dependent (10 nM to 1 uM) and time-
dependent manner (0.5 h to 24 h). MK-2206 inhibited levels of p(Thr308)-AKT and a downstream target, p(Thr246)-PRAS40,
but did not change levels of p(Thr202/Tyr204)ERK or p(Thr13/Tyr185)SAPK/JNK, demonstrating specificity of MK-2206 for
AKT. Additionally, MK-2206 treatment of PRB23 cells resulted in a significant increase in levels of progesterone receptor B
(PRB) protein. Microarray analysis of PRB23 cells identified PDK4 as the most highly upregulated gene among 70
upregulated genes in response to R5020. Inhibition of AKT further upregulated progestin-mediated expression of PDK4 but
did not affect another progestin-responsive gene, SGK1. Treatment of PRB23 cells with R5020 and MK-2206 independently
decreased viability of cells while the combination of R5020 and MK-2206 caused the greatest decrease in cell viability.
Furthermore, mice with xenografted tumors treated with MK-2206 alone or with progesterone alone exhibited modest
reductions in their tumor volume. The largest decrease in tumor size was observed in the mice treated with both MK-2206
and progesterone; these tumors exhibited the least proliferation (Ki67) and the most apoptosis (cleaved caspase-3) of all the
treatment groups. In summary, inhibition of AKT stabilizes the Progesterone Receptor B and augments progesterone
response in endometrial cancer cells that have hyperactivated AKT.
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Introduction
Endometrial cancer is the most common gynecologic malig-
nancy in the United States. In 2010, 43,470 new cases were
anticipated resulting in 7950 deaths [1]. The vast majority of
endometrial cancer cases are related to unopposed estrogen action
are referred to as Type I endometrial cancers. The most common
genetic mutation that occurs in approximately 50–80% of all cases
in Type I endometrial cancer is in the tumor suppressor gene
PTEN [2,3]. A mutation in the PTEN gene results in downstream
constitutive activation of the phosphatidylinositol 39-kinase
(PI3K)/AKT pathway [4]. AKT is a serine/threonine kinase that
activates different pathways promoting cellular survival and
inhibiting apoptosis [4,5]. It has been previously demonstrated
that there are increased levels of activated AKT in endometrial
cancer and that this may portend a poor prognosis in these
patients [6]. Additionally, it has been shown that inhibition of the
AKT pathway in endometrial cancer cells results in increased
apoptosis, thus showing that modulation of this pathway could
play an important therapeutic role [7,8].
Endometrial cancer is usually treated with surgical removal of
the uterus and adjuvant therapy as indicated by the specific
pathology. For early stage disease this treatment results in excellent
5-year survival rates of greater than 90% [9]. However, this
definitive surgery precludes any further fertility. As obesity rates
increase among the population, this results in increasing numbers
of younger women with endometrial cancer and fertility-sparing
therapy will become more invaluable. Currently, progestins are
used as primary therapy in advanced or recurrent disease, in
patients who are not operative candidates due to medical
morbidity, and in patients hoping to preserve their future fertility.
Multiple case series of patients treated with progestins have been
published with encouraging, though not absolute, results. Re-
sponse rates for endometrial hyperplasia with atypia have ranged
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range from 50–70% (reviewed in [10]). For those patients who do
not respond to progestin therapy, hysterectomy is recommended.
This clinical situation is common as the percentage of patients
younger than 45 diagnosed with endometrial cancer now ranges
from 5 to 29% [10,11].
Progesterone mediates its inhibitory effects on the endometrium
and endometrial cancer via the progesterone receptor (PR), an
intracellular steroid receptor with A and B isoforms. An increase in
the response rates to progestin therapy and improved survival
outcomes have been reported in tumors with a higher percentage
of PR [12]. PRA lacks 164 amino acids from the N-terminus and
both isoforms are translated from individual mRNA species of
a single gene under the control of distinct promoters and are
considered functionally distinct [13]. While the specific roles for
PRA and PRB remain unclear in endometrial cancer, studies
suggest that PRB may be the primary isoform responsible for the
growth inhibitory and tumor suppressive actions of progesterone
in vitro. In PRB-stably transfected Ishikawa cells, MPA treatment
resulted in inhibition of proliferation, migration, and invasion,
while PRA-stably transfected Ishikawa cells failed to inhibit these
processes [14,15]. Additionally, PRB-transfected Hec50co cells
treated with progesterone demonstrated significant reductions in
cell proliferation and invasion, whereas Hec50co cells expressing
PRA had only modest inhibitory effects [16].
MK-2206 is an orally active, allosteric inhibitor of AKT.
Numerous preclinical studies have demonstrated efficacy in
inhibiting AKT and promoting cancer cell death as a single agent
as well as in combination with other chemotherapeutic agents
[17,18,19,20]. Clinical trials are in progress using this novel
compound for cancer therapy for various solid tumors. MK-2206
was shown to be generally well tolerated at doses up to 60 mg by
mouth QOD and resulted in plasma concentrations within the
accepted therapeutic range [21]. Currently, there is an open phase
II trial sponsored by the NCI for patients with advanced or
recurrent endometrial cancer. The primary outcomes are pro-
gression- free survival and objective tumor response.
In this study, we report that inhibition of the AKT pathway by
MK-2206 results in decreased viability and increased apoptosis of
endometrial cancer cells. In addition, inhibition of AKT increases
PRB protein levels, modifies the expression of progestin-regulated
genes, and synergizes with progestin to decrease tumor volume of
xenografts. Combinatorial treatment with progestins and AKT
inhibitors could be considered to sensitize endometrial adenocar-
cinoma to progestin therapy.
Materials and Methods
Ethics Statement
All animal experiments were approved by Northwestern
University Animal Care Committee.
Endometrial Cancer Cells
PRB23 Ishikawa cells were obtained from L. Blok (Erasmus
University, Netherlands). Ishikawa cells originated from a well-
differentiated endometrial adenocarcinoma with a known PTEN
mutation [14]. The PRB23 cells were generated by stable
transfection of the pcDNA3.1 PRB expression vector into Ishikawa
cells devoid of endogenous PR [14]. The PRB23 cells were
maintained in DMEM/F12 with 10% FBS, sodium pyruvate,
penicillin/streptomycin, hygromycin, and G418. At approximate-
ly 60–80% confluence, the cells were serum starved overnight in
DMEM/F12. The cells were then treated the next day with
vehicle, 100 nM MK-2206 (2 h pretreatment), 10 nM R5020, or
a combination of the MK-2206 and R5020. MK-2206 (Merck)
was obtained through the Cancer Therapy Evaluation Program.
Western Blot
Whole cell lysates were obtained on ice using the M-PER
Mammalian lysis solution (Thermo Scientific) supplemented with
protease and phosphatase inhibitors (Sigma). The concentration of
protein in the lysates was measured using the Micro BCA kit
(Thermo Scientific). Isolated protein samples were run on 8%
acrylamide gels and then transferred onto polyvinylidene difluor-
ide membranes (Whatman). Membranes were blocked in 5%
Bovine Serum Albumin (BSA, Sigma) in TBS-T at room
temperature for one hour. Membranes were then incubated
overnight at 4uC with primary antibodies against phosphorylated
(Ser473)-AKT, phosphorylated (Thr 308)-AKT, phosphorylated
PRAS40, PRAS40, phosphorylated(Thr202/Tyr 204) ERK,
ERK, (pThr183/Tyr185) SAPK/JNK, JNK, cleaved PARP,
cleaved Caspase 3 (Cell Signaling), and PR (Dako). The blots
were washed four times in TBS-T at room temperature and then
incubated with secondary peroxidase-conjugated goat anti-rabbit
or goat anti-mouse antibody for one hour at room temperature.
The membranes were developed with the ECL Super Signal West
Femto detection kit (Thermo Scientific). The membranes were
stripped using Restore Western Blot Stripping Buffer (Pierce) and
probed with an antibody to beta-actin (Sigma) for a loading
control.
Cell Viability
To assess for cell viability, the AlamarBlue Cell Viability
Reagent (Invitrogen) was used. PRB23 cells were seeded in a 96-
well clear bottom black plate at approximately 1,500 cells per well
in a 37uC incubator. The cells were allowed to attach overnight
and the next day, were washed with PBS and then serum starved
overnight in serum-free DMEM/F12. The next day, the cells were
pre-treated with 1 mM MK-2206 for one hour and then treated
with 100 nM R5020 for 120 hours. At the end of the treatment
time, 10 mL of AlamarBlue reagent was added to each well for two
hours and then the fluorescence signal was measured on the
Synergy HT plate reader from Bio-Tek with the KC4 3.4 software
at 530/590 nm to determine cell viability.
Microarray Analysis and Statistical Analysis
Three separate PRB-Ishikawa cell cultures were used for
microarray analysis. The experimental conditions were vehicle
or treatment with 10 nM R5020 for 2 h. All RNA samples were
processed at the Genomics Core Facility in the Center for
Genetic Medicine at Northwestern University (Chicago, IL).
The quality of total RNA was evaluated using the Bioanalyzer
2100 (Agilent Technologies, Inc., Santa Clara, CA). 1.5 mgo f
each RNA sample, with 260/280 and 28S/18S ratio of greater
than 1.8, was used to make double-stranded cDNA. Quality
checks and probe level processing of the Illumina microarray
data were further made with the R Bioconductor package, lumi
(http://www.bioconductor.org/packages/release/bioc/html/
lumi.html). Data processing also included a normalization
procedure utilizing the quantile normalization method [22] to
reduce the obscuring variation between microarrays, which
might be introduced during the processes of sample preparation,
manufacturing, fluorescence labeling, hybridization, and/or
scanning. Hierarchical clustering and Principal Component
Analysis were performed on the normalized signal data to
assess the sample relationship and variability. Probes absent in
all samples were filtered out according to Illumina’s detection p-
values in the downstream analysis. Differential gene expression
MK-2206 and Progestin in Endometrial Cancer Cells
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linear model analysis using the bioconductor package limma, in
which an empirical Bayes method was used to moderate the
standard errors of the estimated log-fold changes of gene
expression, and resulted in a more stable inference and
improved power, especially for experiments with small numbers
of microarrays ([23]; http://www.bioconductor.org/packages/
release/bioc/html/limma.html). The moderated t-statistic p-
values derived from the limma analysis above were further
adjusted for multiple testing by Benjamini and Hochberg’s
method to control false discovery rate (FDR). The lists of
differentially expressed genes were obtained by the FDR criteria
of ,5% and fold change cutoff of .1.5, and visualized by
volcano plots.
Real Time PCR
RNA was isolated from cells using TRIzol reagent (Invitrogen)
according to the manufacturer’s protocol. Concentration and
purity of extracted RNA were determined using the ND-1000
Spectrophotometer (NanoDrop). Total RNA samples were DNase
I (Zymo Research) treated to remove any contaminating DNA.
Total RNA was reverse-transcribed with the Smart MMLV
reverse transcriptase (Invitrogen) for the synthesis of cDNA using
the manufacturer’s protocol. Real-time PCR was performed using
specific primers (Applied Biosystems) to PDK4 and SGK1 and the
housekeeping gene TBP. The fold change in expression was
calculated using the DDCt method [24], with TBP as an internal
control. All PCR reactions were carried out on an ABI PRISM
7000 Sequence Detection System (Applied Biosystems) for 40
cycles (95uC for 15 s, 60uC for 1 min) after 10 min incubation at
95uC.
Tumor Xenografts
Six-week old CD-1 nude, ovariectomized female mice were
purchased from Charles River Laboratories. All animal experi-
ments were approved by Northwestern University Animal Care
Committee. One million PRB23 cells were suspended in 1:2 PBS/
Matrigel (BD Biosciences) in a total volume of 100 mL and
subcutaneously injected into the right and left dorsum of each
mouse. A total of 32 mice were injected in order to have 8 mice
per treatment group. The tumors were allowed to grow for
8 weeks. Out of 32 mice, tumors grew in 28 mice. In addition, 2
mice died for unknown reasons. The remaining 26 mice were
divided into 4 groups, vehicle (6), progesterone (7), MK-2206 (7),
and MK-2206+progesterone (6). Progesterone pellets (50 mg, 21-
day release for 2.4 mg/day) were implanted subcutaneously. The
mice were given 120 mg/kg of MK-2206, 3 times per week for
9 days in a volume of 0.3 mL of 30% Captisol. All toxicity studies
have been performed in rodents by Merck and 120 mg/kg is the
dose recommended to study effects on tumors without causing
toxicity [25]. The vehicle control group mice were given 0.3 mL of
30% Captisol. Mice were weighed before and after treatments.
Tumor sizes were measured with calipers through the course of
8 weeks as well as after treatments. Tumor volumes were
calculated using the formula:
Tumor volume =1/2(length 6 width)
2 [25]. Tumors were excised
and processed for immunohistochemistry.
Immunohistochemistry
Tissues were fixed in formalin and paraffin embedded, and
4 mm tissue sections were placed on glass slides. The tumor
sections were de-paraffinized. Heat induced epitope retrieval
was then performed in a 10 nM sodium citrate buffer with
0.05% Tween (Sigma) at pH 6.0. The citrate buffer was pre-
warmed in a water bath at 99uC and then the slides were
placed in the buffer for 45 minutes. The slides were allowed to
cool for 30 minutes at room temperature and were washed in
TBS-T for 5 minutes. The Dako EnVision HRP IHC kit was
used. 3% hydrogen peroxide was applied to the tissue sections
for 10 minutes followed by 2 washes for 10 minutes in TBS-T.
Protein block was applied for 30 minutes at room temperature.
The tissue sections were then incubated with primary antibodies
to PR (Dako) or cleaved Caspase 3 (Cell Signaling) overnight at
4uC in a humidified chamber. Anti-rabbit or anti-mouse
secondary antibody was then applied to the tissue sections for
1 hour at room temperature and then washed in TBS-T twice
for 5 minutes. DAB solution was applied to each tissue section
for 5 minutes and then rinsed. Mayer’s Hematoxylin was used
to counterstain and the slides were rinsed. The sections were
then placed in a solution of 28% ammonium hydroxide and
then rinsed. The sections were dehydrated via 2 changes of
95% ethanol, 2 changes of 100% ethanol, and 2 changes of
Xylene. The sections were then mounted onto cover slips using
Cytoseal XYL mounting media (Richard-Allan Scientific). The
slides were then visualized using the Axiovert 200 (Zeiss)
microscope and pictures taken with the Zeiss Axiocam camera.
Results
MK-2206 Inhibits AKT
It has previously been reported that Ishikawa cells carry a PTEN
mutation and this results in constitutive downstream activation of
AKT [7,8]. In order to determine whether MK-2206 inhibited
AKT in the PRB23 cells, cells were treated with increasing
concentrations of MK-2206 (0–1 mM) and incubated for various
times (0–24 h) (Fig. 1A, 1B). Phosphorylated (Ser473)-AKT was
detected in cells treated with vehicle and levels progressively
declined with increasing concentrations of MK-2206 (Fig. 1A).
Total AKT levels were not affected by treatment with MK-2206.
Levels of p(Ser473)-AKT decreased, as early as 1 h, and remained
lower than vehicle treated cells at 24 h (Fig. 1B). Levels of
p(Thr308)-AKT also declined with 100 nM MK-2206 treatment
at both 4 h and 24 h (Fig. 1C). PRAS40 is a direct substrate of
AKT and levels of p(Thr246)-PRAS40 decreased upon MK-2206
treatment at 4 h and 24 h, indicating that the AKT activity is
decreased (Fig. 1C). Next, in order to demonstrate that MK-2206
was specific to the AKT pathway in PRB23 cells, levels of other
phosphorylated kinases, which are not direct targets of AKT were
measured. Levels of p(Thr202/Tyr204)-ERK as well as
p(Thr183/Tyr185)-JNK did not change upon MK-2206 treat-
ment either at 4 h or 24 h (Fig. 1C).
Inhibition of AKT Increases PRB Protein Levels
Interestingly, treatment with MK-2206 also resulted in a signif-
icant increase in PRB levels in the PRB23 cells, indicating that
AKT affects levels PR protein in these cells (Fig. 2A). Given the
antagonistic function of progesterone in the endometrium, the
implications of modulating PR levels are significant. First,
a microarray was performed to identify PRB-regulated genes in
PRB23 cells. Specifically, PRB23 cells were treated with 10 nM
R5020 for 2 h and thus only the early response genes to progestins
would be identified. A total of 70 genes were significantly
upregulated by more than 1.5 fold and 16 genes were down-
regulated significantly (Fig. 2B). The most highly upregulated
genes were PDK4 (9.92-fold), TIPARP (7.79-fold), and SGK1
(4.41-fold). Genes were further analyzed with the ‘functional
annotation clustering’ tool of the Database for Annotation,
Visualization and Integrated Discovery (DAVID) [26]. Genes
MK-2206 and Progestin in Endometrial Cancer Cells
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The category that included the highest number of genes that were
regulated by R5020 was ‘‘phosphoproteins’’ and the second
highest were genes that its products were associated with the
nucleus (Fig. 2C).
Next, the influence of AKT on PRB target genes was examined.
PRB23 cells were treated with 10 nM R5020 in the presence or
absence of 100 nM MK-2206. Expression of PDK4 and SGK1
were then measured by real time PCR. PDK4 and SGK1 were
categorized as phosphoproteins. As depicted in Figure 3, both
PDK4 and SGK1 were significantly upregulated by R5020,
confirming the microarray data. MK-2206 treatment alone did
not influence expression of any of the genes tested compared to
vehicle-treated cells. When cells were treated in combination with
R5020 and MK-2206, expression of PDK4 significantly increased,
however, SGK1 expression did not change with the combination
treatment compared to R5020 alone. This differential regulation
of PRB target genes in the PRB23 cells when AKT is inhibited
strongly suggests a more complex mechanism of regulating genes
than simply increasing levels of PRB protein.
MK-2206 and Progestin Decreases Cell Viability and
Tumor Size
In order to measure the effects of AKT and progestin on cancer
cell viability, PRB23 cells were treated with R5020 in the presence
or absence of MK-2206 and cell viability was measured. While
R5020 and MK-2206 independently decreased viability of cells
over the course of 5 days the combination of R5020 and MK-
2206 caused the greatest decrease in viability (Fig. 4).
Next, the effects of progesterone and MK-2206 were tested in
xenografted tumors that developed from subcutaneous injection of
the PRB23 cells in nude mice. The tumors were grown for
8 weeks and subsequently treated for 9 days with vehicle, pro-
gesterone, MK-2206, or progesterone+MK-2206 (Fig. 5A).
Weight of mice did not change significantly with the treatments
(Fig. 5B). Compared to the mice treated with vehicle, the mice
treated with MK-2206 alone or progesterone alone exhibited
modest reductions in their tumor volume based on fold change
from the tumor size before treatment. The largest decrease in
tumor size was observed in the mice treated with both MK-2206
and progesterone (Fig. 5C).
Figure 1. The AKT inhibitor, MK-2206 inhibits AKT. PRB-specific Ishikawa (PRB23) cells were treated with A) increasing concentrations (0–1 uM)
of MK-2206 for 24 h and B) 100 nM MK-2206 for various times (0–24 h). Protein levels of p(Ser473)-AKT, AKT and actin were measured by Western
blot. C) PRB23 cells were treated with 100 nM MK-2206 for 4 h or 24 h and levels of p(Thr308)-AKT, AKT, p(Thr246)PRAS40, PRAS40, p(Thr202/Tyr204)
ERK, ERK, p(Thr183/Tyr185) SAPK/JNK, JNK and actin were measured by western blot.
doi:10.1371/journal.pone.0041593.g001
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using antibodies to progesterone receptor, Ki67 and cleaved
caspase-3 (Fig. 6). Staining for PR was evident in the tumors,
although not all cells were positive for PR. Progesterone treatment
decreased levels of PR both in the presence and absence of MK-
2206. In contrast, MK-2206 treatment promoted an increase in
PR protein levels in the tumors, similar to what was observed in
endometrial cancer cells (Fig. 2A). Proliferation of the cells was
Figure 2. MK-2206 increases PRB protein. A) PRB-specific Ishikawa (PRB23) cells were treated with vehicle, 100 nM MK-2206, 10 nM R5020, or
a combination of MK-2206+R5020 (M+R) for 4 h and protein levels of p(Ser473)-AKT, AKT, PRB, and actin were measured by Western blot. B)
Microarray analysis of PRB23 cells treated with vehicle or 10 nM R5020 was performed and genes significantly regulated by 1.5-fold or greater were
identified. C) Gene ontology categories analysis was done using DAVID for genes regulated by more than 1.5-fold by R5020.
doi:10.1371/journal.pone.0041593.g002
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gesterone, MK-2206 as well as the combination progestero-
ne+MK-2206 treatment. The lowest levels of Ki67 staining was
observed with the combined treatment, suggesting that the
combined treatment more effectively decreases proliferation of
the cancer cells. Levels of cleaved caspase-3, an indicator of
apoptosis, were negligible in the tumors of vehicle treated mice,
while staining was evident in the tumors of progesterone or MK-
2206 treated mice. The combined treatment resulted in the
highest expression of cleaved caspase-3, indicative of increased
apoptosis.
Discussion
In this study, we demonstrated that MK-2206 efficiently
decreased levels of p(Ser473)-AKT and p(Thr308)-AKT in the
PTEN-mutated Ishikawa cells. As a result, levels of p(Thr246)-
PRAS40, a downstream target of AKT, decreased as well,
indicative that the activity of AKT was inhibited by MK-2206.
This inhibitor did not affect levels of other kinases, such as pERK
and pJNK demonstrating specificity for this compound to the
AKT pathway. Inhibition of AKT also increased levels of PRB.
Previously, we demonstrated that a different AKT inhibitor, API-
59CJ-OMe (EMD4Biosciences), also significantly increased PR
levels in PRB23 Ishikawa cells [8]. Gu et al., [27], recently showed
that inhibition of PI3K using LY294002 increased PR levels in
Ishikawa cells. The influence of the AKT pathway on PR
expression and function has not been studied in detail and the
mechanisms by which this increase in PR protein occurs are
currently being explored in our lab. Our current working
hypothesis centers on the role of AKT in decreasing sensitivity
to progesterone in endometrial cancer. Decreasing PR levels was
the first piece of evidence supportive of our hypothesis. It was
assumed that increased PR levels should enhance PR transcrip-
tional function, however, data reveal that PR action is more
complex, since not all progesterone-regulated genes were influ-
enced by AKT inhibition. It is well established that, like other
steroid hormone receptors, regulation of genes by PR involves
numerous interactions with other transcription factors, DNA,
coregulators, and chromatin remodeling complexes. PR action is
gene specific in that different mechanisms are employed at
different sites of the chromatin. Our microarray analysis identified
PDK4 to be the most highly upregulated gene (more than 50-fold
increase) with short-term progestin treatment. This was also a gene
that was further increased with progestin when AKT was
inhibited, indicating that overactive AKT in the Ishikawa cells
dampens the progesterone action on this particular gene. It has
been shown that PDK4 is also upregulated by glucocorticoids,
through GR, in HepG2 cells [28]. They demonstrated that
overexpression of PKBa abrogated the dexamethasone stimulation
of the PDK4 promoter which supports our findings. Furthermore,
they demonstrated that FOXO1, which is directly phosphorylated
by AKT and exported to the cytoplasm, was required for the GR-
mediated upregulation of PDK4. We have demonstrated a co-
operation of PR and FOXO1 in regulating genes in endometrial
Figure 3. Influence of MK-2206 on R5020-regulated genes.
PRB23 cells were treated with vehicle, 10 nM R5020, 100 nM MK-2206,
or a combination of MK-2206+R5020 (M+R) and gene expression of
PDK4 and SGK1 was measured using real-time PCR. Data are presented
as fold changes from vehicle treated samples and represent the mean
6 sem of 6 independent experiments. ‘‘*’’ denotes statistical
significance compared to vehicle control. P#0.05.
doi:10.1371/journal.pone.0041593.g003
Figure 4. Combination of MK-2206 and R5020 significantly
decreases cell viability. PRB23 cells were treated with vehicle,
100 nM R5020, 1 uM MK-2206, or a combination of MK-2206+R5020
(M+R) for 5 days and cell viability was measured using the Alamar Blue
assay. Data are presented as % viability from vehicle treated samples
and represent the mean 6 sem of 4 independent experiments.
doi:10.1371/journal.pone.0041593.g004
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upregulation by progestins requires both PR and FOXO1 in
endometrial cancer cells. Thus, when AKT is active, insufficient
levels of FOXO1 are available to act in the nucleus and expression
of PDK4 is dampened. It would be interesting to determine the
significance of the PR and FOXO1 cooperation in the other
progesterone-responsive genes that were influenced by AKT
inhibition in endometrial cancer.
PDK4 is a kinase that inactivates the pyruvate dehydrogenase
complex (PDC). The PDC generates acetyl-CoA, which is the
precursor for fatty acid synthesis and energy production by the
Krebs cycle. PDC activity is regulated by PDKs and PDC
phosphatases to phosphorylate or dephosphorylate the E1a
component of the complex. This regulation is important to control
glucose and lipid metabolism. Upregulation of PDK4 by
progestins and a further enhancement of this increase upon
MK-2206 treatment suggests that progestins can act to inactivate
the PDC and inhibit the conversion of pyruvate to acetyl-CoA.
This inhibition of acetyl-CoA production may consequently lead
to the utilization of alternate metabolic pathways such as
glycolysis. Given the central role that PDK4 plays in regulating
the choice between glycolysis and oxidative phosphorylation,
PDK4 has been implicated in a number of different cancers. It has
previously been shown that inhibition of PDK activity is sufficient
to inhibit proliferation and induce apoptosis in lung cancer cells,
suggesting that PDKs may drive tumorigenesis [32]. However,
recent studies have also demonstrated that overexpression of
PDK4 is sufficient to inhibit proliferation of breast cancer cells and
Figure 5. Combination of MK-2206 and R5020 promotes tumor regression. A) PRB23 cells were xenografted subcutaneously in CD1 nude
mice. After 8 weeks, mice were treated with vehicle, 120 mg/kg MK-2206 orally, 3 times a week for 9 days, progesterone or combination of MK-2206
and progesterone. B) Weights of mice were measured before and after treatments and C) tumors were measured before and after treatments and
volume was calculated. ‘‘*’’ denotes statistical significance compared to vehicle control. P#0.05.
doi:10.1371/journal.pone.0041593.g005
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cancer tissues [33]. The specific role that PDK4 plays in
endometrial cancer remains to be deciphered.
Preclinical studies have demonstrated MK-2206 to effectively
inhibit the AKT pathway as well as decrease proliferation and
tumor growth of various cancer cell lines [25]. It has also been
shown that the combination of MK-2206 and chemotherapeutic
agents is more effective in inhibiting tumor growth [25]. MK-2206
along with a MEK inhibitor was demonstrated to have a synergistic
effect on tumor growth and led to increased survival rates in mice
bearing highly aggressive human lung tumors [34]. MK-2206 was
able to restore sensitivity of resistant cells to sorafenib, a tyrosine
kinase inhibitor, to induce apoptosis in hepatocellular carcinoma
cells [35]. In combination with Gefitinib, a small molecule
inhibitor of the EGFR tyrosine kinase, MK-2206 effectively
promoted apoptosis in malignant glioma [17]. In addition to
proliferation and apoptosis, it has been shown that MK-2206
inhibits metastasis of head and neck squamous cell carcinoma
[18]. There are currently over 20 NCI-sponsored clinical phase I
or II trials using MK-2206 for various malignancies. This
compound, as a single agent, has been shown to be safe in
humans and orally effective [21]. There is a phase II clinical trial
currently underway utilizing MK-2206 for patients with PIK3CA
mutation in recurrent or advanced endometrial carcinoma. MK-
2206 is also being tested in combination with different chemo-
therapeutic regimens for various malignancies. The use of MK-
2206, which has been shown to be safe and clinically effective in
humans, could be considered in combination with progestin
therapy for endometrial cancer patients who may be resistant to
conventional therapy with progesterone. Furthermore, those
patients that have endometrial tumors that are PTEN-negative,
or carry mutations in the PIK3CA gene, could be considered for
combinatorial MK-2206 and progestin therapy.
Progestin therapy has been used for decades for many women as
an alternative to surgery for endometrial neoplasias. Studies have
shown a 50–70% overall response rate for patients treated with
high dose progestins as primary therapy. Close follow-up of
patients treated with progestins is usually done, even in the
responders because of the substantial rate of recurrence
[36,37,38,39,40]. As risk factors and incidence of endometrial
cancer are rising, the use of progestins will become more prevalent
for prevention and treatment of this disease. Improving response
rates to progestins will require a clearer understanding of the
molecular mechanisms of progesterone receptor action and the
pathways that influence its function.
We have demonstrated that inhibition of AKT not only
increases PRB protein levels, but that it acts with progestin to
decrease cell viability, increase apoptosis, and cause a decrease in
tumor size. Our results indicate that inhibition of the AKT
pathway could improve the efficacy of progestins in the treatment
of endometrial cancer.
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